Neuroblastoma Treatment Market Size, Share, Analysis, Trends, Growth Report, 2030

Neuroblastoma Treatment Market

Neuroblastoma Treatment Market by Therapy (Surgery, Chemotherapy, Immunotherapy, and Radiotherapy), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Drug Stores): Global Industry Perspective, Comprehensive Analysis and Forecast, 2021 – 2028

Published Date: 27-Sep-2021 Category: Medical Device Report Format : PDF Pages: 144 Report Code: ZMR-18 Status : Published
Market Size in 2020 Market Forecast in 2028 CAGR (in %) Base Year
USD 437.5 Million USD 600.5 Million 4.1% 2020

Neuroblastoma Treatment Industry Perspective:

The neuroblastoma treatment market accounted for USD 437.5 Million in 2020 and is expected to reach USD 600.5 Million by 2028, growing at a CAGR of 4.1% from 2021 to 2028.

Neuroblastoma is a type of pediatric cancer that is developed in the nervous system of babies and young children. It grows in immature nerve tissue known as neuroblasts. It affects the adrenal glands present just above the kidneys. Neuroblastoma can also develop in nerve tissue in the spinal cord, abdomen, chest, or neck. It can spread to other parts of the body. Due to the higher rate of neuroblastoma, the need for treatment is necessary for the coming years. The increasing population and frequency of this cancer is the prime reason for the treatment of Neuroblastoma and hence there is the growth rate for this market is necessary.

Global Neuroblastoma Treatment MarketRequest Free Sample

COVID-19 Impact Analysis

According to data gathered from countries such as UK & U.S. the treatment for neuroblastoma was on a halt as young children and babies get affected by coronavirus at a rapid rate. CCLG, one of the active groups of doctors in the UK has also recently published data about children with cancer who have had coronavirus, to provide a clear picture of the impact of the virus on young cancer patients. Based on the information gathered by this project, CCLG’s updated advice includes recommendations for the extremely vulnerable and vulnerable groups. Thus, the market for neuroblastoma was on a steady growth rate due to COVID-19.

Neuroblastoma Treatment Market: Growth Factors

Neuroblastoma is rare cancer but it’s the most common cancer in babies. According to a health organization in the United States, about 800 children are diagnosed with neuroblastoma. It almost always develops before age 5. It can occur in babies before they are born. Neuroblastoma is very rare in children over age 10.

There are four stages of neuroblastoma such as Stage L1, Stage L2, Stage M, and Stage MS. Neuroblastoma happens when immature nerve tissues (neuroblasts) grow out of control. The cells become abnormal and continue growing and dividing, forming a tumor. A genetic mutation (a change in the neuroblast’s genes) causes the cells to grow and divide uncontrollably.

Healthcare providers are not sure what causes the genetic mutation and still, there is no technology to find the main cause of this cancer to grow. Due to this reason, the need treatment is necessary and government bodies and healthcare companies are investing huge funds in research and development for this treatment. In coming years due to higher birthrate the need for this treatment is the major factor concerning the growth of the neuroblastoma treatment market.

Neuroblastoma Treatment Market: Report Scope

Report Attributes Report Details
Report Name Neuroblastoma Treatment Market Research Report
Market Size in 2020 USD 437.5 Million
Market Forecast in 2028 USD 600.5 Million
Growth Rate CAGR of 4.1%
Number of Pages 188
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered United Therapeutics Corporation, Apeiron Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., Bayer AG, Sun Pharmaceutical Industries, Inc., and Sartorius AG.
Segments Covered By Therapy, By Distribution Channel, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)
Base Year 2021
Historical Year 2016 to 2020
Forecast Year 2019 - 2026
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Therapy Segment Analysis Preview

The therapy segment is subdivided into Surgery, Chemotherapy, Immunotherapy, and Radiotherapy. The surgery segment is one of the major segments that contribute about 45% of total global revenue for the neuroblastoma treatment market, followed by other segments such as chemotherapy, immunotherapy, and radiotherapy. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. A surgical oncologist is a doctor who specializes in treating cancer using surgery.

If the cancer has not spread, surgery can sometimes be used to remove the entire tumor. Chemotherapy is the use of drugs to destroy cancer cells, usually by ending the cancer cell's ability to grow and divide. Chemotherapy is given by a pediatric oncologist or a medical oncologist, a doctor who specializes in treating cancer with medication. Radiotherapy is the use of high-energy X-rays or other particles to destroy cancer cells.

Regional Analysis Preview

North America dominated the market in 2020, accounting for over 35.0% share of the global revenue. The market growth is due to factors such as the high prevalence of neuroblastoma in the region, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the United States every year. The above statistics prove that the high prevalence of the disease is boosting the market in the region.

Key Market Players & Competitive Landscape

Major market players in Neuroblastoma Therapy Market are

  • United Therapeutics Corporation
  • Apeiron Biologics AG
  • Baxter
  • Cellectar Biosciences. Inc.
  • Pfizer, Inc., MacroGenics. Inc.
  • Bayer AG
  • Sun Pharmaceutical Industries, Inc.
  • Sartorius AG.

Brief information about 10 companies will also be provided in the report. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were a few techniques adopted by most of the companies providing the neuroblastoma therapy market in recent years. For instance, on June 23, 2021, Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of neuroblastoma cancer. The FDA-approved product DANYELZA is launched by the company which will benefit neuroblastoma patients.

The Neuroblastoma Therapy Market is segmented as follows:

By Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content


FrequentlyAsked Questions

Although neuroblastoma is a rare kind of cancer, it affects infants most frequently. Approximately 800 youngsters in the United States have received a neuroblastoma diagnosis, claims a health organisation. It almost always appears before the age of five. Babies may experience it before birth. In youngsters above the age of 10, neuroblastoma is extremely uncommon.

According to analysts at Zion Market Research, the Neuroblastoma Treatment market accounted for USD 437.1 Million in 2020 and is expected to reach USD 600.5 Million by 2028

The Global Neuroblastoma Treatment Market is anticipated to record a CAGR of nearly 4.1% from 2020 to 2028.

In 2020, North America dominated the market, contributing more than 35.0% of worldwide revenue. The high frequency of neuroblastoma in the area and the well-established healthcare infrastructure are some of the main factors responsible for its significant market share.

The Global Neuroblastoma Treatment Market is led by players like United Therapeutics Corporation, Apeiron Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., Bayer AG, Sun Pharmaceutical Industries, Inc., and Sartorius AG.

Choose License Type

  • zion payment modes


Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed